Second-generation BTK inhibitors for patients with WM: What is the potential for improving outcomes?
Dr Alessandra Tedeschi highlights the effectiveness and limitations of first-generation Bruton’s tyrosine kinase (BTK) inhibitors in the management of people with Waldenström’s macroglobulinaemia, and outlines emerging efficacy data from clinical trials of second-generation BTK inhibitors.view bio and disclosures 1/3 Next Chapter
Maximizing outcomes for patients with WM: Adverse events associated with second-generation BTK inhibitors
Dr Alessandra Tedeschi overviews the adverse event profile of first-generation BTK inhibitors in treating Waldenström’s macroglobulinaemia, and walks us through the safety data from recent clinical trials of emerging second-generation BTK inhibitors.view bio and disclosures 2/3 Next Chapter
Learning Objectives & Overview
In this activity, Dr Alessandra Tedeschi, an expert in Waldenström’s macroglobulinaemia (WM), discusses emerging second-generation Bruton’s tyrosine kinase (BTK) inhibitors in development for the treatment of people with WM, and provides an overview of current management practices.
After watching this activity, participants should be better able to:
- Evaluate the new and emerging efficacy data for second-generation BTK inhibitors in patients with WM
- Summarize the adverse events associated with second-generation BTK inhibitors
- Review current management recommendations for people with Waldenström’s macroglobulinaemia
Faculty & Disclosures
Dr Alessandra Tedeschi
Niguarda Cancer Centre, Milan, Italy
Dr Alessandra Tedeschi is a Consultant Haematologist in the Oncology/Haematology Department of the Niguarda Cancer Center, Milan, Italy.
Dr Tedeschi gained her medical degree from the University of Bologna, Bologna, Italy and completed her specialism in haematology specialty at the University of Ancona, Italy. From 1996 to 1999, she carried out research in the Haematology Department of the Niguarda Cancer Center and completed an internship in the Leukemia Department of the MD Anderson Cancer Center, Houston, Texas, USA.
Dr Tedeschi has a specific interest in the treatment of chronic lymphoproliferative disorders, in particular chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia. She is principal investigator for numerous clinical trials.
Consulting services for AbbVie, AstraZeneca, BeiGene and Janssen-Cillag SpA